1:5 Stock Split: Multibagger Small Cap Stock Rallies 18% After Setting Record Date

Small cap pharmaceuticals sector stock, Gujarat Themis Biosyn witnessed its fresh 52-week high for second day in a row on Friday. The stock hit 52-week high value of Rs 1021 apiece on Sept 28 and traded 52-week high value of Rs 1044.00 apiece today. Current market price of Gujarat Themis Biosyn share is Rs 1027.00 apiece on BSE. Gujarat Themis shares offered return of 27% in last 1-month. It announced sub-division of shares on September 20 in 1:5 ratio and set October 10 as record date.Check details below:

Gujarat Themis Declares Record Date For Sub-Division/Stock Split: According to the regulatory filing of the company dated September 20, 2023 "With reference to the captioned subject and in terms of Regulation 42 of the SEBI Listing Regulations, the Company has fixed Tuesday, 10th October, 2023 as the 'Record Date' for the purpose of determining the eligibility of Shareholders for the purpose of sub-division/split of every one fully paid-up Equity share having face value Rs. 5/- (Rupees Five only) each in the authorised share capital of the Company, into 5 (five) fully paid-up Equity shares having face value of Rs. 1/- (Rupee One only) each, as approved by the shareholders at the 42nd Annual General Meeting of the Company held on 9th September, 2023."

Gujarat Themis Shares Outlook & Return In 5-Years: Current market price of Gujarat Themis share on BSE is Rs 1027.20 per share with intraday gain of 0.90%. The stock hit back-to-back new 52-week high for second day today. In last 1-week, Gujarat Themis stock offered 18% return, soared 49% in last 6-months, surged 32% YTD, and rallied 71% in last 1-year. Gujarat Themis share gained 74% in last 2-years, rallied 377% in last 3-years, and rose 2828% in last 5-years. The stock witnessed spurt in volume by 2.09 times on September 28. Its market capitalisation is Rs 1497.40 crore. The stock's 52-week high price is Rs 1044.00 per share and 52-week low price is Rs 572.10 per share, respectively.

Gujarat Themis Financials: The firm for the quarter ended June 30, 2023 declared its net sales at Rs 49.59 crore, up 10.33% as against Rs 44.94 crore declared in June 2022. Its quarterly net profit has been declared at Rs 17.72 crore in June 2023, down 0.27% as against Rs 17.77 crore in June 2022. It declard its EBITDA at Rs 24.58 crore in June 2023, up 1.57% as compared to Rs 24.20 crore in June 2022.

Gujarat Themis About: Incorporated in 1981 as a joint sector company with GIIC Ltd and Chemosyn (P) Ltd. It commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin, according to its official website.

Disclaimer

The stock just highlights the rally in shares and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.